JP2001192069A - Package for container filled with chemicals containing bicarbonate - Google Patents
Package for container filled with chemicals containing bicarbonateInfo
- Publication number
- JP2001192069A JP2001192069A JP2000322124A JP2000322124A JP2001192069A JP 2001192069 A JP2001192069 A JP 2001192069A JP 2000322124 A JP2000322124 A JP 2000322124A JP 2000322124 A JP2000322124 A JP 2000322124A JP 2001192069 A JP2001192069 A JP 2001192069A
- Authority
- JP
- Japan
- Prior art keywords
- bicarbonate
- solution
- container
- filled
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 title claims abstract description 69
- 239000000126 substance Substances 0.000 title claims abstract description 69
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 67
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000001301 oxygen Substances 0.000 claims abstract description 48
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 48
- 239000005022 packaging material Substances 0.000 claims abstract description 41
- 239000004033 plastic Substances 0.000 claims abstract description 26
- 229920003023 plastic Polymers 0.000 claims abstract description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910001873 dinitrogen Inorganic materials 0.000 claims abstract description 11
- 239000007789 gas Substances 0.000 claims description 38
- 239000001569 carbon dioxide Substances 0.000 claims description 32
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 32
- 239000012298 atmosphere Substances 0.000 claims description 18
- 239000006096 absorbing agent Substances 0.000 claims description 17
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 13
- 239000003792 electrolyte Substances 0.000 claims description 13
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 235000011089 carbon dioxide Nutrition 0.000 abstract 3
- 230000001131 transforming effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 67
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- -1 polypropylene Polymers 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002615 hemofiltration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010027417 Metabolic acidosis Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- NDQKGYXNMLOECO-UHFFFAOYSA-N acetic acid;potassium Chemical compound [K].CC(O)=O NDQKGYXNMLOECO-UHFFFAOYSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000004 hemodialysis solution Substances 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000005001 laminate film Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005672 polyolefin resin Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Landscapes
- Package Specialized In Special Use (AREA)
- Packages (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
【0001】[0001]
【発明が属する技術分野】本発明は、重炭酸塩含有薬液
を充填した容器を包装した包装体に関する。さらに詳細
には、該重炭酸塩含有薬液を充填した容器をガス非透過
性包装材にて包装し、該包装材のピンホール発生を検知
すること、かつ、該重炭酸塩含有薬液の安定性を維持
し、かつ、酸素検知剤の効力を保持する重炭酸塩含有薬
液充填容器包装体に関する。The present invention relates to a package for packaging a container filled with a bicarbonate-containing chemical solution. More specifically, a container filled with the bicarbonate-containing chemical solution is packaged in a gas-impermeable packaging material, and pinhole generation of the packaging material is detected, and the stability of the bicarbonate-containing chemical solution is determined. The present invention relates to a bicarbonate-containing chemical liquid-filled container package which maintains the above-mentioned properties and maintains the efficacy of the oxygen detector.
【0002】[0002]
【従来の技術】血液透析、血液濾過、血液濾過透析およ
び腹膜透析などの人工腎臓療法の最も重要な役割は、水
分、代謝産物の除去のほかに、代謝性アシドーシスの矯
正である。これらの手法に使用される透析液は全て緩衝
剤(アルカリ化剤)を含み、血液透析においては重炭酸
ナトリウムの形の重炭酸塩が本来の緩衝剤であった。し
かし、重炭酸ナトリウム溶液は常温でも反応して炭酸ガ
スになり、濃度が変化したり、他の電解質成分として含
まれるカルシウムイオンなどと容易に反応し、沈殿を起
こすなど製剤化が困難であることから、他の緩衝剤、例
えば乳酸塩あるいは酢酸塩が、これらに代わって使用さ
れてきた。乳酸塩あるいは酢酸塩は体内で重炭酸にまで
代謝されて緩衝作用を発揮する。しかしながら、肝障
害、糖尿病、外科侵襲時等の大手術で代謝異常のある患
者、急性腎不全や多蔵器不全などの重症患者に、乳酸塩
や酢酸塩を含む薬液を投与すると、酢酸不耐性による血
圧低下や気分不良などの副作用が発生しやすいことやア
シドーシス是正効果が低いなどの問題があり、近年、上
記血液の緩衝剤として、乳酸塩等の代わりに、再び、重
炭酸塩を使用する血液透析液、血液濾過用置換が使用さ
れるようになってきている。BACKGROUND OF THE INVENTION The most important role of artificial kidney therapy, such as hemodialysis, hemofiltration, hemofiltration dialysis and peritoneal dialysis, is the correction of metabolic acidosis, as well as the removal of water and metabolites. The dialysate used in these procedures all contained a buffer (alkalizing agent), and in hemodialysis the bicarbonate in the form of sodium bicarbonate was the original buffer. However, sodium bicarbonate solution reacts at room temperature to form carbon dioxide gas, changes its concentration, easily reacts with calcium ions contained as other electrolyte components, etc., and causes difficulties in formulation such as precipitation. Thus, other buffers, such as lactate or acetate, have been used in their place. Lactate or acetate is metabolized to bicarbonate in the body to exert a buffering action. However, when a drug solution containing lactate or acetate is administered to patients with metabolic abnormalities due to major surgery such as liver injury, diabetes, or surgical invasion, or severe patients such as acute renal failure or multiple reservoir failure, acetic acid intolerance occurs. There are problems such as side effects such as lowering of blood pressure and bad mood due to poor mood and the effect of correcting acidosis is low.In recent years, instead of lactate, bicarbonate is used again as a buffer for the blood. Hemodialysis fluid, hemofiltration replacements are being used.
【0003】この重炭酸塩を含有する薬液とは、通常、
重炭酸ナトリウムを含む水溶液であり、必要により電解
質あるいは糖類を含有する。このような重炭酸塩を含有
する薬液は、一般に重炭酸ナトリウムが分解して炭酸ナ
トリウムと炭酸ガスとなる。この分解反応が進むに従っ
て、充填された薬液中の炭酸ガスが放出され、薬液のp
Hが上昇する。このようにpHが上昇した重炭酸塩含有
薬液を患者に投与すると、本来の機能である代謝性アシ
ドーシスの矯正が行われず、むしろ、副作用の危険性が
あり、所期の目的が達成されない。[0003] The chemical containing bicarbonate is usually
It is an aqueous solution containing sodium bicarbonate, and contains an electrolyte or saccharides as necessary. In such a chemical solution containing bicarbonate, sodium bicarbonate is generally decomposed into sodium carbonate and carbon dioxide gas. As the decomposition reaction progresses, carbon dioxide gas in the filled chemical is released, and p of the chemical is released.
H rises. When a bicarbonate-containing drug solution having such an increased pH is administered to a patient, metabolic acidosis, which is an essential function, is not corrected, but rather there is a risk of side effects, and the intended purpose is not achieved.
【0004】一方、重炭酸塩含有溶液を充填する容器と
して、ガス非透過性のガラス容器を使用した場合には、
分解生成したガスが反応系外に出ることがなく、再び薬
液に吸収されて、pHは安定している。ところが、ガラ
ス容器は重いうえに破損しやすく、取り扱いが困難であ
ることから、近年、プラスチック製容器に代替されてい
る。プラスチック容器としては、通常、高いガス透過性
を有する材質のものが使用されるため、この容器に重炭
酸塩含有薬液を充填すると、加熱滅菌時や長期保存時に
発生した炭酸ガスを薬液に再吸収することなく、容器壁
から外部へ放出され、薬液のpH変化が生じる。そのた
めに、該薬液を充填した容器をガス非透過性包装材で包
装して、炭酸ガス放出による薬液の変化を防止すること
が一般に行われている。On the other hand, when a gas-impermeable glass container is used as a container for filling a bicarbonate-containing solution,
The gas generated by decomposition does not go out of the reaction system, is absorbed again by the chemical solution, and the pH is stable. However, glass containers are heavy, are easily damaged, and are difficult to handle. Therefore, glass containers have recently been replaced with plastic containers. As a plastic container is usually made of a material with high gas permeability, filling this container with a bicarbonate-containing chemical solution reabsorbs the carbon dioxide gas generated during heat sterilization or during long-term storage. Without being released from the container wall, the pH of the chemical solution changes. For this purpose, it is common practice to package a container filled with the chemical solution with a gas-impermeable packaging material to prevent a change in the chemical solution due to the release of carbon dioxide gas.
【0005】しかしながら、ガス非透過性包装材にピン
ホールが生じた場合、容器壁から放出された炭酸ガスが
さらに包装材の外部へ放出され、容器に充填された薬液
のpHがやはり上昇し、また、炭酸ガスの放出により重
炭酸塩の含量が低下するなどの変化が生じる。このよう
な薬液を過誤に投与すると、副作用の危険性が懸念され
る。そのため、容器と包装材との間に酸素検知剤、pH
変化により変色するインジケーターなどのピンホールチ
ェッカーを導入することが必要となる(特開平8-164185
号公報、特開平11-139461号公報、WO97/48365など)。
また、酸素検知剤の効力を保持するためには、脱酸素剤
の併用が必要となる(特開平8-164185号公報)。[0005] However, when a pinhole occurs in the gas impermeable packaging material, the carbon dioxide gas released from the container wall is further released to the outside of the packaging material, and the pH of the chemical solution filled in the container also rises. In addition, changes such as a decrease in the content of bicarbonate due to the release of carbon dioxide gas occur. If such a drug solution is incorrectly administered, there is a concern about the risk of side effects. Therefore, between the container and the packaging material, oxygen detector, pH
It is necessary to introduce a pinhole checker such as an indicator that changes color due to a change (Japanese Patent Laid-Open No. 8-164185).
JP, JP-A-11-139461, WO97 / 48365, etc.).
Further, in order to maintain the effectiveness of the oxygen detector, it is necessary to use a deoxidizer in combination (Japanese Patent Application Laid-Open No. 8-164185).
【0006】しかし、一般に脱酸素剤として使用されて
いる鉄粉系脱酸素剤を使用すると、重炭酸塩から放出さ
れた炭酸ガスが脱酸素剤の主成分である活性炭および鉄
に吸収され、逆に重炭酸塩含有溶液の安定性が維持でき
ないなどの問題が生じる。そこで、重炭酸塩含有薬液の
安定性を高める対策として、前記容器と包装材との空間
部に一定濃度の炭酸ガスを封入したり(特開昭61-355号
公報、特許第2750373号公報、特許第2811035号公報、特
許第2890142号公報)、炭酸ガス発生型の脱酸素剤を使
用しているのが現状である(特許第2527532号公報、特
許第27505329号公報、特許第2890142号公報)。However, when iron powder-based oxygen absorbers, which are generally used as oxygen absorbers, are used, the carbon dioxide gas released from the bicarbonate is absorbed by activated carbon and iron, which are the main components of the oxygen absorber. In addition, problems such as the inability to maintain the stability of the bicarbonate-containing solution occur. Therefore, as a measure for increasing the stability of the bicarbonate-containing chemical solution, a certain concentration of carbon dioxide gas is sealed in the space between the container and the packaging material (Japanese Patent Laid-Open No. 61-355, Japanese Patent No. 2750373, Patent Nos. 2811035 and 2890142), and at present, a carbon dioxide-generating type oxygen scavenger is used (Japanese Patent No. 2527532, Japanese Patent No. 27505329, Japanese Patent No. 2890142). .
【0007】ところが、重炭酸塩含有薬液充填容器と包
装材との空間部に炭酸ガスを封入する際、封入する炭酸
ガスの濃度に特に注意する必要があり、炭酸ガス封入量
が多すぎると、充填された薬液のpH低下および該薬液
中の重炭酸塩含量が増加して問題となる。また、上記空
間部に炭酸ガス発生型脱酸素剤を導入し、かつ、該空間
部を通常の空気状態のままで包装を行うと、該脱酸素剤
の特性により、吸収した酸素量に相当する量の炭酸ガス
が放出されて、薬液のpH低下および重炭酸塩含量の増
加が生じる。そこで、薬液の安定性を保持するために
は、炭酸ガス吸収剤を用いるか、あるいは、容器と包装
材の空間部に窒素ガスを封入して、酸素量を極力少なく
するなどの方法が用いられている(特開平8-164185号公
報)。However, when encapsulating carbon dioxide in the space between the bicarbonate-containing drug-filled container and the packaging material, it is necessary to pay particular attention to the concentration of carbon dioxide to be enclosed. There is a problem in that the pH of the filled chemical decreases and the bicarbonate content in the chemical increases. In addition, when a carbon dioxide-generating type deoxidizer is introduced into the space, and packaging is performed while the space is in a normal air state, the amount of oxygen absorbed corresponds to the amount of oxygen absorbed due to the characteristics of the oxygen absorber. An amount of carbon dioxide is released, causing a drop in the pH of the drug solution and an increase in bicarbonate content. Therefore, in order to maintain the stability of the chemical solution, a method such as using a carbon dioxide gas absorbent or enclosing nitrogen gas in the space between the container and the packaging material to minimize the amount of oxygen is used. (JP-A-8-164185).
【0008】上記したように、重炭酸塩含有薬液を充填
する容器と包装材との空間部に、炭酸ガス発生型脱酸素
剤を導入した場合、該空間部の容量によっては炭酸ガス
が多量に発生して、容器に充填された薬液の安定性を維
持するために、さらに炭酸ガス吸収剤等を導入して、充
填された薬液のpHおよび重炭酸含量を調整するなどの
煩雑な操作が必要となる。また、薬液充填容器と包装材
との空間部に炭酸ガスを封入する場合、封入量のバラツ
キにより、保存初期段階におけるpHの変動が生じやす
いなどの欠点がある。As described above, when a carbon dioxide-generating type oxygen scavenger is introduced into the space between the container filled with the bicarbonate-containing chemical solution and the packaging material, a large amount of carbon dioxide gas depends on the capacity of the space. In order to maintain the stability of the drug solution generated and filled in the container, complicated operations such as introducing a carbon dioxide gas absorbent and adjusting the pH and bicarbonate content of the filled drug solution are necessary. Becomes Further, when carbon dioxide gas is sealed in the space between the liquid medicine filling container and the packaging material, there is a disadvantage that the pH tends to fluctuate in the initial stage of storage due to the variation in the amount of sealing.
【0009】[0009]
【発明が解決しようとする課題】本発明の目的は、重炭
酸塩含有薬液の安全性を高めるため、包装材のピンホー
ルチェッカーとして酸素検知剤を封入し、かつ、重炭酸
塩含有薬液の安定性を高めるために、炭酸ガスを封入す
ることなく、重炭酸塩含有薬液の変化を阻止できる該薬
液充填容器包装体を提供することである。SUMMARY OF THE INVENTION An object of the present invention is to enhance the safety of a bicarbonate-containing chemical by enclosing an oxygen detector as a pinhole checker for packaging materials and to stabilize the bicarbonate-containing chemical. It is an object of the present invention to provide a chemical-filled container package capable of preventing a change in a bicarbonate-containing chemical solution without enclosing carbon dioxide gas in order to enhance the property.
【0010】[0010]
【課題を解決するための手段】本発明者らは、上記目的
を達成するために種々鋭意研究した結果、重炭酸塩含有
薬液をプラスチック製容器に充填し、ガス非透過性の包
装体内に、該容器とともに脱酸素剤としてカテコール型
脱酸素剤および酸素検知剤を封入した容器包装体を用い
ることにより、該容器と該包装材との空間部に外部より
積極的に炭酸ガスの封入を施さなくても、充填された薬
液の安定性及び酸素検知剤の効力を長期間、維持するこ
とが可能であることを見いだし、本発明に到達した。Means for Solving the Problems As a result of various studies to achieve the above object, the present inventors have filled a plastic container with a bicarbonate-containing chemical solution, and placed it in a gas-impermeable packaging body. By using a container package in which a catechol-type oxygen absorber and an oxygen detector are enclosed as an oxygen absorber together with the container, the space between the container and the packaging material is not actively filled with carbon dioxide from outside. However, they have found that it is possible to maintain the stability of the filled chemical solution and the efficacy of the oxygen detector for a long period of time, and have reached the present invention.
【0011】すなわち、本発明は重炭酸塩を含有する薬
液を充填したプラスチック製容器がガス非透過性包装材
で包装され、該プラスチック容器と該包装材との空間部
が、積極的に炭酸ガス濃度調整を施さない雰囲気であ
り、さらに、該空間部に脱酸素剤および酸素検知剤が収
容されてなる重炭酸塩含有薬液充填容器包装体である。That is, according to the present invention, a plastic container filled with a chemical solution containing bicarbonate is packaged in a gas-impermeable packaging material, and the space between the plastic container and the packaging material is positively increased by carbon dioxide gas. A bicarbonate-containing chemical liquid-filled container package having an atmosphere in which the concentration is not adjusted and further containing a deoxidizer and an oxygen detector in the space.
【0012】また、本発明の一態様としては、重炭酸塩
を含有する薬液を充填したプラスチック製容器がガス非
透過性包装材で包装され、該プラスチック容器と該包装
材との空間部が、窒素ガス雰囲気または積極的に炭酸ガ
スが存在しない空気雰囲気であり、さらに、該空間部に
脱酸素剤および酸素検知剤が収容されてなる重炭酸塩含
有薬液充填容器包装体がある。According to another aspect of the present invention, a plastic container filled with a chemical solution containing bicarbonate is packaged in a gas-impermeable packaging material, and the space between the plastic container and the packaging material is There is a bicarbonate-containing chemical liquid-filled container package in which a nitrogen gas atmosphere or an air atmosphere in which carbon dioxide gas does not actively exist, and in which a deoxidizer and an oxygen detector are contained in the space.
【0013】また、本発明の一態様としては、前記プラ
スチック製容器は複室容器であり、前記重炭酸塩を含有
する薬液は、pHが7.6〜8.6である重炭酸塩溶液
(A)およびpHが3.0〜5.0である電解質および
/または還元糖を含有する溶液(B)からなり、該溶液
(A)および該溶液(B)を混合した際のpHが7.0
〜7.6である薬液であり、該複室容器内の一室に溶液
(A)および他室に溶液(B)が充填されていることを
特徴とする。In one embodiment of the present invention, the plastic container is a multi-chamber container, and the bicarbonate-containing chemical solution is a bicarbonate solution (pH: 7.6 to 8.6). A) and a solution (B) containing an electrolyte and / or a reducing sugar having a pH of 3.0 to 5.0, and a pH of 7.0 when the solution (A) and the solution (B) are mixed. 0
薬 7.6, characterized in that the solution (A) is filled in one chamber and the solution (B) is filled in another chamber in the multi-chamber container.
【0014】[0014]
【発明の実施の態様】本発明の薬液は、重炭酸塩含有薬
液であり、例えば、pHが7.0〜7.6である重炭酸
塩含有薬液であり、好ましくは、pHが7.6〜8.6
である重炭酸塩含有溶液(A)および電解質および/ま
たは糖類を含有し、pHが3.0〜5.0である溶液
(B)からなり、溶液(A)および溶液(B)を混合し
た際のpHが7.0〜7.6である。本発明において使
用する溶液(A)は、重炭酸塩および必要により電解質
および/または糖類を含有する。重炭酸塩としては、従
来から各種透析液及び電解質輸液に使用されるものでよ
く、炭酸水素ナトリウム、炭酸水素カリウム等の炭酸水
素塩の単独水溶液あるいはこれら混合液であり、さら
に、必要により重炭酸塩以外の電解質イオンおよび糖類
を含むことが可能である。ここで、電解質イオンとして
は、重炭酸と反応して不溶性塩を生じないナトリウムイ
オン、カリウムイオンなどが挙げられる。糖類として
は、グルコース、キシリトール、ソルビトールなどが挙
げられ、還元糖であるグルコースが特に好ましい。さら
にグリセロールなどの多価アルコールも使用できる。BEST MODE FOR CARRYING OUT THE INVENTION The chemical solution of the present invention is a bicarbonate-containing chemical solution, for example, a bicarbonate-containing chemical solution having a pH of 7.0 to 7.6, preferably a pH of 7.6. ~ 8.6
(A) and a solution (B) containing an electrolyte and / or a saccharide and having a pH of 3.0 to 5.0. The solution (A) and the solution (B) were mixed. PH at that time is 7.0 to 7.6. The solution (A) used in the present invention contains a bicarbonate and, if necessary, an electrolyte and / or a saccharide. As the bicarbonate, those conventionally used for various dialysates and electrolyte infusions may be used. The bicarbonate may be a single aqueous solution of sodium bicarbonate such as sodium bicarbonate or potassium bicarbonate, or a mixture thereof. It is possible to include electrolyte ions and sugars other than salts. Here, examples of the electrolyte ion include a sodium ion and a potassium ion that do not generate an insoluble salt by reacting with bicarbonate. Examples of the saccharide include glucose, xylitol, and sorbitol, and glucose, which is a reducing sugar, is particularly preferable. Further, polyhydric alcohols such as glycerol can be used.
【0015】また、本発明において調製される溶液
(B)は、少なくともカルシウムおよびマグネシウムな
どの陽イオンを含む溶液であり、さらに、カルシウムお
よびマグネシウム以外の他の電解質イオンおよび糖類、
たとえば還元糖を含むことも可能である。The solution (B) prepared in the present invention is a solution containing at least cations such as calcium and magnesium, and further contains electrolyte ions and saccharides other than calcium and magnesium,
For example, it can contain a reducing sugar.
【0016】本発明において使用する電解質は、従来か
ら使用されているものは何れも使用可能であり、例え
ば、塩化ナトリウム、酢酸ナトリウム、クエン酸ナトリ
ウム、塩化カリウム、ヨウ化カリウム、クエン酸カリウ
ム、酢酸カリウム、クエン酸カルシウム、グリセロリン
酸カルシウム、グルコン酸カルシウム、硫酸マグネシウ
ム、塩化マグネシウム等をあげることができる。As the electrolyte used in the present invention, any of those conventionally used can be used. For example, sodium chloride, sodium acetate, sodium citrate, potassium chloride, potassium iodide, potassium citrate, acetic acid Potassium, calcium citrate, calcium glycerophosphate, calcium gluconate, magnesium sulfate, magnesium chloride and the like can be mentioned.
【0017】本発明における溶液(A)の製造に当たっ
ては、通常は、pHを7.6〜8.6、好ましくは7.
9〜8.5、最も好ましくは8.1〜8.3に調整す
る。In the production of the solution (A) in the present invention, the pH is usually 7.6 to 8.6, preferably 7.
It is adjusted to 9 to 8.5, most preferably 8.1 to 8.3.
【0018】本発明において使用する溶液(B)は、還
元糖および電解質を含有する。これらの溶液は常法に従
って調製し、通常は、pHを3.0〜5.0、好ましく
は3.7〜4.3、最も好ましくは3.9〜4.1に調
整する。The solution (B) used in the present invention contains a reducing sugar and an electrolyte. These solutions are prepared according to a conventional method, and the pH is usually adjusted to 3.0 to 5.0, preferably 3.7 to 4.3, and most preferably 3.9 to 4.1.
【0019】本発明に使用する容器は、その形状、厚さ
は特に限定されないが、薬液流入口および薬液排出口を
有する単室または複数の室を有するプラスチック製容
器、例えばバッグである。特に、複数の室を有する柔軟
なプラスチック製容器が好ましい。その材質は、従来か
ら使用されているポリプロピレン、ポリエチレンなどの
ポリオレフィン系樹脂、ポリ塩化ビニル系樹脂を含む一
般的な熱可塑性樹脂であり、医療用安全性が高く高圧蒸
気滅菌を行う場合には少なくとも105℃の温度に耐え
るものが望まれる。本発明では容器のガス透過性は特に
制限されない。複数の室を有する容器では、該室と室と
の隔離壁の全部または一部は該容器外から隔離開放が可
能であり、該室と室との連通可能にする隔離開放手段で
形成された医療用プラスチック製容器である。また、隔
離開放が可能な手段は剥離強度が容器周辺部を溶着させ
た部分よりも小さな接着強度を有するか、あるいは接着
部において、接着強度を低下させるための部材を挿入す
ることにより形成される。The container used in the present invention is not particularly limited in its shape and thickness, but is a plastic container having one or more chambers having a chemical liquid inlet and a chemical liquid outlet, for example, a bag. In particular, a flexible plastic container having a plurality of chambers is preferred. The material is conventionally used polyolefin resin such as polypropylene and polyethylene, and general thermoplastic resin including polyvinyl chloride resin.It is highly safe for medical use and at least when high-pressure steam sterilization is performed. Those that withstand a temperature of 105 ° C. are desired. In the present invention, the gas permeability of the container is not particularly limited. In a container having a plurality of chambers, all or a part of a partition wall between the chambers can be separated and opened from the outside of the container, and is formed by a separating and opening means that allows communication between the chamber and the chamber. This is a medical plastic container. In addition, the means capable of separating and opening is formed by inserting a member for lowering the adhesive strength in the adhesive portion, or having a lower adhesive strength than the portion where the container peripheral portion is welded. .
【0020】さらに、これらの容器を収容するガス非透
過性包装材は、例えばエチレンビニルアルコール共重合
体(EVOH)、ポリエチレンテレフタレート(PE
T)ポリ塩化ビニリデン(PVDC)、ナイロンなどか
ら構成された包装材、そしてこれらの素材にシリカやア
ルミナなどのガスバリア性物質の蒸着処理を行った包装
材、また、これらの素材を組み合わせた多層フィルムか
ら作製された包装材が使用できる。ここでいうガス非透
過性とは、通常、酸素透過率が10ml/m2/24時間/1気圧
以下、好ましくは1ml/m2/24時間/1気圧以下のもであれ
ばよい。また、該包装材は酸素検知剤の変色を確認でき
る透明性を有し、かつ、液体非透過性の包装材を使用す
ることが望ましい。Further, the gas impermeable packaging material for accommodating these containers is, for example, ethylene vinyl alcohol copolymer (EVOH), polyethylene terephthalate (PE).
T) Packaging materials composed of polyvinylidene chloride (PVDC), nylon, etc., packaging materials obtained by subjecting these materials to vapor deposition of a gas barrier material such as silica or alumina, or multilayer films combining these materials Can be used. The gas impermeable here, usually oxygen permeability 10 ml / m 2/24 hours / 1 atmosphere or less, preferably as long as also the following 1 ml / m 2/24 hours / 1 atm. In addition, it is desirable to use a packaging material that has transparency so that the discoloration of the oxygen detector can be confirmed and is liquid-impermeable.
【0021】本発明に使用する重炭酸塩含有薬液の容器
包装体は、上記薬液を充填したプラスチック製容器をガ
ス非透過性包装材に収容する際、酸素検知剤と脱酸素剤
を封入する。該空間部は脱酸素剤の酸素吸収効果を発揮
しやすいように、周囲にさらに大きな空間が存在するこ
とが望ましい。酸素検知剤としては、酸素の存在によ
り、その物性を変化させるものであれば、特に制限され
ないが、好ましくは酸素の存在により、変色をともなう
もの、例えば、三菱瓦斯化学(株)製エージレスアイな
どが例示される。また、脱酸素剤としては、好ましくは
炭酸ガス発生量の少ない脱酸素剤、たとえば、カテコー
ル系脱酸素剤があり、具体的には、炭酸ガス分率が1.
0〜8.0vol%である脱酸素剤がある。このような脱
酸素剤としては、王子化工株式会社製「タモツD」及び
「タモツV」などが例示される。The container package of the bicarbonate-containing chemical solution used in the present invention encloses an oxygen detecting agent and a deoxidizing agent when the plastic container filled with the chemical solution is accommodated in a gas-impermeable packaging material. The space preferably has a larger space around it so that the oxygen absorbing effect of the oxygen scavenger can be easily exerted. The oxygen detector is not particularly limited as long as it changes its physical properties in the presence of oxygen. Preferably, the oxygen detector has a color change due to the presence of oxygen, for example, Ageless Eye manufactured by Mitsubishi Gas Chemical Co., Ltd. Is exemplified. Further, as the oxygen scavenger, there is preferably an oxygen scavenger having a small carbon dioxide gas generation amount, for example, a catechol-based oxygen scavenger. Specifically, the carbon dioxide gas fraction is 1.
There is an oxygen scavenger that is 0-8.0 vol%. Examples of such an oxygen scavenger include “Tamotsu D” and “Tamotsu V” manufactured by Oji Chemical Industries, Ltd.
【0022】また、該空間部のガス状態については、酸
素検知剤の変色を迅速に生じさせるためには、空間部の
空気を窒素で置換することが好ましい。しかし、空間部
の窒素ガス置換を行わない空気状態であっても、空間部
の容量を調整し、かつ、脱酸素剤として炭酸ガスの発生
量及び吸収量が共に少ないカテコール系脱酸素剤を同封
して包装すれば良い。このような脱酸素剤としては、上
記したカテコール系脱酸素剤、例えば、王子化工株式会
社製「タモツD」及び「タモツV」などが例示される。As for the gas state in the space, it is preferable to replace the air in the space with nitrogen in order to promptly change the color of the oxygen detector. However, even in the air state where the nitrogen gas is not replaced in the space, the capacity of the space is adjusted, and a catechol-based oxygen absorber that generates and absorbs a small amount of carbon dioxide gas is enclosed as an oxygen absorber. And wrap it. Examples of such oxygen absorbers include the above-mentioned catechol-based oxygen absorbers, for example, “Tamotsu D” and “Tamotsu V” manufactured by Oji Chemical Industries, Ltd.
【0023】本発明では重炭酸塩を含有する薬液を充填
したプラスチック製容器がガス非透過性包装材で包装さ
れ、該プラスチック容器と該包装材との空間部が、積極
的に炭酸ガス濃度調整を施さない雰囲気であることが特
徴であり、その一態様としては、窒素ガス雰囲気または
積極的に炭酸ガスが存在しない空気雰囲気である。積極
的に炭酸ガス濃度調整を施さない雰囲気とすることによ
り、重炭酸塩の含量低下やpH上昇を防止することが可
能である。また、該空間部に酸素検知剤が収容されてな
ることにより、保存時に包装材にピンホールが生じた場
合、重炭酸塩濃度の低下および薬液のpH上昇が生じて
も事前に検知することが可能である。さらに、該空間部
に脱酸素剤が存在することにより、酸素検知剤の効力を
維持することが可能となる。また、薬液充填容器として
2室容器を用いることにより、重炭酸塩および還元糖の
安定性が高まり、従来の重炭酸塩含有薬液より安全性及
び安定性の面で優れている。In the present invention, a plastic container filled with a chemical solution containing bicarbonate is packaged in a gas-impermeable packaging material, and the space between the plastic container and the packaging material is positively adjusted for carbon dioxide gas concentration. It is characterized by an atmosphere in which no nitrogen gas is applied, and one embodiment thereof is a nitrogen gas atmosphere or an air atmosphere in which carbon dioxide gas does not actively exist. By setting the atmosphere in which the carbon dioxide concentration is not actively adjusted, it is possible to prevent the bicarbonate content from decreasing and the pH from increasing. In addition, if a pinhole occurs in the packaging material during storage due to the oxygen detector being contained in the space, even if a decrease in the bicarbonate concentration and an increase in the pH of the chemical solution occur, it can be detected in advance. It is possible. Further, the presence of the oxygen scavenger in the space makes it possible to maintain the effectiveness of the oxygen sensing agent. In addition, by using a two-chamber container as the chemical liquid filling container, the stability of bicarbonate and reducing sugar is increased, and the safety and stability are superior to the conventional bicarbonate-containing chemical liquid.
【0024】[0024]
【実施例】以下に、実施例、比較例及び試験例に基づい
て、本発明をより詳細に説明するが、本発明はこれらの
実施例に限定されるものではない。EXAMPLES Hereinafter, the present invention will be described in more detail based on examples, comparative examples, and test examples, but the present invention is not limited to these examples.
【0025】実施例1 下記表1の組成に従い、溶液(A)の各成分を常温で適
量の蒸留水に溶解し、該溶液中に炭酸ガスを吹き込ん
で、pHを約7.4に調整し、注射用水を加えて全量を
10Lとした後、孔径 0.22μmのメンブレンフィル
ターで濾過した。この溶液をポリプロピレン製の2室容
器のI室に各500ml充填した。一方、下記表2の組
成に従い、溶液(B)の各成分を適量の蒸留水に溶解
し、注射用水を加えて全量を10Lとした。この溶液を
同様の方法で濾過し、ポリプロピレン製の2室容器の他
室に各500ml充填した後、常法に従って、121
℃、20分間にて高圧蒸気滅菌を行った。このようにし
て得られた上記重炭酸塩含有薬液容器を室温に冷却後、
脱酸素剤(大江化学(株)製タモツD、炭酸ガス分率
1.0〜4.0vol%))および酸素検知剤(三菱瓦斯
化学(株)製エージレスアイ)と共に包装材(シリカ蒸
着PET/ナイロン/CPPのラミネートフィルム)に
収容し、容器と包装材との空間部を高純度窒素ガスを用
いて窒素置換し(置換率95%以上)、密封して重炭酸
塩含有薬液収容プラスチック製容器の包装体を製造し
た。 Example 1 According to the composition shown in Table 1 below, each component of the solution (A) was dissolved in an appropriate amount of distilled water at room temperature, and carbon dioxide gas was blown into the solution to adjust the pH to about 7.4. After adding water for injection to make the total volume 10 L, the mixture was filtered through a membrane filter having a pore size of 0.22 μm. This solution was filled into the I room of a two-compartment polypropylene container in an amount of 500 ml each. On the other hand, according to the composition shown in Table 2 below, each component of the solution (B) was dissolved in an appropriate amount of distilled water, and water for injection was added to make a total volume of 10 L. This solution was filtered in the same manner, and each of the two chambers made of polypropylene was filled with 500 ml each in another chamber.
High-pressure steam sterilization was performed at 20 ° C. for 20 minutes. After cooling the bicarbonate-containing chemical solution container thus obtained to room temperature,
A packaging material (silica-deposited PET / silica-evaporated PET / Nylon / CPP laminate film), and the space between the container and the packaging material is purged with nitrogen using a high-purity nitrogen gas (replacement rate of 95% or more), sealed, and sealed to a plastic container containing a bicarbonate-containing chemical liquid. Was manufactured.
【0026】[0026]
【表1】 [Table 1]
【0027】[0027]
【表2】 [Table 2]
【0028】実施例2 容器と包装材との空間部を窒素ガス雰囲気に代えて、空
気雰囲気としたことを除いて、実施例1と同様にして、
重炭酸塩含有薬液収容プラスチック製容器の包装体を製
造した。 Example 2 The procedure of Example 1 was repeated, except that the space between the container and the packaging material was replaced with an air atmosphere instead of a nitrogen gas atmosphere.
A package of a plastic container containing a bicarbonate-containing drug solution was manufactured.
【0029】実施例3 脱酸素剤として、大江化学社製「タモツD」(炭酸ガス
分率1.0〜4.0vol%)に代えて、大江化学社製
「タモツV」(炭酸ガス分率1.0〜8.0vol%)を
使用した点および容器と包装材との空間部を窒素雰囲気
に代えて、空気雰囲気とした点を除き、実施例1と同様
にして、重炭酸塩含有薬液充填プラスチック製容器の包
装体を製造した。 Example 3 As a deoxidizing agent, "Tamotsu V" (carbon dioxide content: 1.0-4.0 vol%) manufactured by Oe Chemical Co., Ltd. 1.0-8.0 vol%), and the bicarbonate-containing chemical solution was prepared in the same manner as in Example 1, except that the space between the container and the packaging material was replaced with a nitrogen atmosphere and an air atmosphere was used. A package of a filled plastic container was manufactured.
【0030】比較例1 脱酸素剤を「タモツD」に代えて、「エージレスZH」
(三菱瓦斯化学(株)製)を使用した点および容器と包
装材との空間部を窒素雰囲気に代えて、空気雰囲気とし
た点を除き、実施例1と同様にして、重炭酸塩含有薬液
充填プラスチック製容器の包装体を製造した。 Comparative Example 1 "Ageless ZH" was used in place of "Tamotsu D" as the oxygen scavenger.
A bicarbonate-containing chemical solution was prepared in the same manner as in Example 1 except that a gas atmosphere (manufactured by Mitsubishi Gas Chemical Co., Ltd.) was used and that the space between the container and the packaging material was replaced with a nitrogen atmosphere and an air atmosphere was used. A package of a filled plastic container was manufactured.
【0031】比較例2 脱酸素剤を「タモツD」に代えて、「エージレスG」
(三菱瓦斯化学(株)製)を使用した点と容器と包装材
との空間部を窒素ガス雰囲気に代えて、空気雰囲気とし
た点を除き、実施例1と同様にして、重炭酸塩含有薬液
充填プラスチック製容器の包装体を製造した。 Comparative Example 2 "Ageless G" was used in place of "Tamotsu D" as the oxygen scavenger.
(Mitsubishi Gas Chemical Co., Ltd.) was used, and the bicarbonate content was the same as in Example 1 except that the space between the container and the packaging material was replaced with a nitrogen gas atmosphere and an air atmosphere was used. A package of a chemical-filled plastic container was manufactured.
【0032】試験例1 実施例1〜3および比較例1〜2で得られた包装体を4
0℃、75%RH条件にて、2ケ月間保存した。該包装
体に収容された容器中の薬液について、pH、異物検査
を測定した。その結果を下記表3に示す。 Test Example 1 The packages obtained in Examples 1 to 3 and Comparative Examples 1 and 2 were
It was stored at 0 ° C. and 75% RH for 2 months. The pH and foreign substance inspection were measured for the drug solution in the container housed in the package. The results are shown in Table 3 below.
【0033】[0033]
【表3】 [Table 3]
【0034】上記表3から、実施例1に示すように、
「タモツD」タイプの脱酸素剤を使用して、薬液容器と
包装体との空間部を窒素置換した薬液が、最もpH変化
が少なく安定であった。また、実施例2または3に示す
ように、容器と包装材との空間部が空気であっても、
「タモツD」タイプあるいは「タモツV」タイプの脱酸
素剤を使用すれば、従来の鉄粉系やアスコルビン酸系の
脱酸素剤を使用した比較例1〜2と比較して、重炭酸塩
含有薬液の安定性が大幅に改善することが明らかとなっ
た。From Table 3 above, as shown in Example 1,
The chemical solution in which the space between the chemical solution container and the package was replaced with nitrogen using a “Tamots D” type oxygen absorber had the lowest pH change and was stable. Further, as shown in Example 2 or 3, even when the space between the container and the packaging material is air,
When the “Tamots D” type or “Tamots V” type oxygen absorber is used, bicarbonate content is higher than that of Comparative Examples 1 and 2 using conventional iron powder or ascorbic acid oxygen absorbers. It was found that the stability of the drug solution was greatly improved.
【0035】[0035]
【発明の効果】本発明では、重炭酸塩含有製剤は炭酸ガ
ス発生量の少ないカテコール系脱酸素剤を使用している
ため、容器と包装材との空間部に外部より積極的に炭酸
ガスあるいは窒素ガスを封入しなくても空気のままで、
薬液の安定性及び酸素検知剤の効力を維持することが可
能である。また、包装材にピンホールが生じても、外部
から酸素が混入した際には、薬液のpHが変化する前
に、酸素検知剤の色が変化することにより、不良品の識
別が可能となる。さらに、本発明では、2室を有するプ
ラスチック製容器に重炭酸塩含有薬液を充填し、該容器
と該包装材の間の空間部にピンホールチェッカーとして
酸素検知剤を封入し、さらに、好ましくはカテコール系
脱酸素剤である脱酸素剤を同封して、製剤の安定性及び
安全性の点で有用性の高い重炭酸含有薬液を充填した容
器包装体を得ることができる。According to the present invention, since the bicarbonate-containing preparation uses a catechol-based deoxidizing agent that generates a small amount of carbon dioxide gas, the carbon dioxide or oxygen is positively applied to the space between the container and the packaging material from the outside. Even if nitrogen gas is not sealed, it remains in air,
It is possible to maintain the stability of the chemical solution and the efficacy of the oxygen detector. Further, even if a pinhole occurs in the packaging material, when oxygen is mixed in from the outside, the color of the oxygen detecting agent changes before the pH of the chemical solution changes, so that defective products can be identified. . Further, in the present invention, a bicarbonate-containing chemical solution is filled in a plastic container having two chambers, and an oxygen detector is sealed as a pinhole checker in a space between the container and the packaging material. By enclosing the oxygen absorber that is a catechol-based oxygen absorber, a container package filled with a bicarbonate-containing chemical solution that is highly useful in terms of stability and safety of the preparation can be obtained.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 河野 悟史 大阪市北区本庄西3丁目9番3号 株式会 社ニッショー内 (72)発明者 佐藤 誠 大阪市北区本庄西3丁目9番3号 株式会 社ニッショー内 (72)発明者 川村 慎一 大阪市北区本庄西3丁目9番3号 株式会 社ニッショー内 (72)発明者 小平 精吾 大阪市北区本庄西3丁目9番3号 株式会 社ニッショー内 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Satoshi Kono 3-9-3 Honjo Nishi, Kita-ku, Osaka City Inside Nissha Corporation (72) Inventor Makoto Sato 3-9-1, Honjo Nishi, Kita-ku, Osaka City Inside Nissha Corporation (72) Inventor Shinichi Kawamura 3-9-3 Honjo Nishi, Kita-ku, Osaka City Inside Nissha Corporation (72) Seigo Inventor Seigo Kodaira 3-9-1, Honjo Nishi, Kita-ku, Osaka Stock Company Inside Nissha
Claims (6)
スチック製容器がガス非透過性包装材で包装され、該プ
ラスチック容器と該包装材との空間部が、積極的に炭酸
ガス濃度調整を施さない雰囲気であり、さらに、該空間
部に脱酸素剤および酸素検知剤が収容されてなる重炭酸
塩含有薬液充填容器包装体。1. A plastic container filled with a bicarbonate-containing chemical solution is packaged with a gas-impermeable packaging material, and the space between the plastic container and the packaging material actively adjusts the concentration of carbon dioxide gas. A bicarbonate-containing chemical liquid-filled container package having an atmosphere not subjected to oxygen treatment and further containing a deoxidizer and an oxygen detector in the space.
スチック製容器がガス非透過性包装材で包装され、該プ
ラスチック容器と該包装材との空間部が、窒素ガス雰囲
気または積極的に炭酸ガスが存在しない空気雰囲気であ
り、さらに、該空間部に脱酸素剤および酸素検知剤が収
容されてなる重炭酸塩含有薬液充填容器包装体。2. A plastic container filled with a bicarbonate-containing chemical solution is packaged with a gas-impermeable packaging material, and the space between the plastic container and the packaging material is filled with a nitrogen gas atmosphere or actively carbonic acid. A bicarbonate-containing chemical liquid-filled container package having an air atmosphere in which no gas is present, and further containing a deoxidizer and an oxygen detector in the space.
い脱酸素剤である請求項1または2記載の重炭酸塩含有
薬液充填容器包装体。3. The package containing a bicarbonate-containing chemical liquid according to claim 1, wherein the oxygen scavenger is an oxygen scavenger that generates a small amount of carbon dioxide gas.
ある請求項1または2記載の重炭酸塩含有薬液充填容器
包装体。4. The package according to claim 1, wherein the oxygen absorber is a catechol-based oxygen absorber.
および必要により電解質および/または還元糖を含有す
る溶液である請求項1または2記載の重炭酸塩含有薬液
充填容器包装体。5. A package containing a bicarbonate-containing chemical solution according to claim 1, wherein the bicarbonate-containing chemical solution is a solution containing a bicarbonate and, if necessary, an electrolyte and / or a reducing sugar.
り、前記重炭酸塩を含有する薬液は、pHが7.6〜
8.6である重炭酸塩溶液(A)およびpHが3.0〜
5.0である電解質および/または還元糖を含有する溶
液(B)からなり、該溶液(A)および該溶液(B)を
混合した際のpHが7.0〜7.6である薬液であり、
該複室容器内の一室に溶液(A)および他室に溶液
(B)が充填されている請求項1または2記載の重炭酸
塩含有薬液充填容器包装体。6. The plastic container is a multi-chamber container, wherein the bicarbonate-containing chemical solution has a pH of 7.6 to 6.
A bicarbonate solution (A) of 8.6 and a pH of 3.0 to 3.0;
A solution (B) containing an electrolyte and / or a reducing sugar having a pH of 5.0 and a pH of 7.0 to 7.6 when the solution (A) and the solution (B) are mixed. Yes,
The bicarbonate-containing drug solution-filled container package according to claim 1 or 2, wherein a solution (A) is filled in one chamber and a solution (B) is filled in another chamber in the multi-chamber container.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000322124A JP3733583B2 (en) | 1999-10-25 | 2000-10-23 | Bicarbonate-containing chemical solution-filled container package |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11-301877 | 1999-10-25 | ||
JP30187799 | 1999-10-25 | ||
JP2000322124A JP3733583B2 (en) | 1999-10-25 | 2000-10-23 | Bicarbonate-containing chemical solution-filled container package |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001192069A true JP2001192069A (en) | 2001-07-17 |
JP3733583B2 JP3733583B2 (en) | 2006-01-11 |
Family
ID=26562910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000322124A Expired - Lifetime JP3733583B2 (en) | 1999-10-25 | 2000-10-23 | Bicarbonate-containing chemical solution-filled container package |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3733583B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000190A1 (en) * | 2003-06-30 | 2005-01-06 | Santen Pharmaceutical Co., Ltd. | Eye perfusate container |
JP2007301205A (en) * | 2006-05-12 | 2007-11-22 | Ajinomoto Co Inc | Container container filled with bicarbonate-containing chemicals |
JP2019037633A (en) * | 2017-08-28 | 2019-03-14 | ニプロ株式会社 | Standard reagent kit for dialysate analysis |
CN109661572A (en) * | 2016-08-30 | 2019-04-19 | 尼普洛株式会社 | Dialyzate analysis standard reagent kit and standard reagent with, dialyzate with and artificial kidney fluid infusion aqueous solution |
-
2000
- 2000-10-23 JP JP2000322124A patent/JP3733583B2/en not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000190A1 (en) * | 2003-06-30 | 2005-01-06 | Santen Pharmaceutical Co., Ltd. | Eye perfusate container |
JP2007301205A (en) * | 2006-05-12 | 2007-11-22 | Ajinomoto Co Inc | Container container filled with bicarbonate-containing chemicals |
EP1854492A3 (en) * | 2006-05-12 | 2007-11-28 | Ajinomoto Co., Inc. | Reservoir assembly for container holding bicarbonate solution |
CN109661572A (en) * | 2016-08-30 | 2019-04-19 | 尼普洛株式会社 | Dialyzate analysis standard reagent kit and standard reagent with, dialyzate with and artificial kidney fluid infusion aqueous solution |
EP3508840A4 (en) * | 2016-08-30 | 2020-04-15 | Nipro Corporation | Standard reagent kit for dialysis fluid analysis, and aqueous solution for standard reagent, dialysis fluid, and artificial kidney fluid replenishment |
JP2019037633A (en) * | 2017-08-28 | 2019-03-14 | ニプロ株式会社 | Standard reagent kit for dialysate analysis |
JP7003493B2 (en) | 2017-08-28 | 2022-02-04 | ニプロ株式会社 | Standard reagent kit for dialysate analysis |
Also Published As
Publication number | Publication date |
---|---|
JP3733583B2 (en) | 2006-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4984033B2 (en) | Container container filled with bicarbonate-containing chemicals | |
US4630727A (en) | Container for a bicarbonate containing fluid | |
JP3879017B2 (en) | Bicarbonate-containing chemical container package and pH indicator | |
CA2482405C (en) | Multiple compartment bag assembly for dialysis fluid | |
JP2811035B2 (en) | Bicarbonate blended liquid and its container | |
JPWO2004108059A1 (en) | Aseptic formulation | |
JP3243387B2 (en) | Plastic container containing bicarbonate-containing chemicals | |
CN105726565A (en) | Sodium citrate Ringer injecta packaged by non-PVC plastics and preparation process of sodium citrate Ringer injecta | |
JP3733583B2 (en) | Bicarbonate-containing chemical solution-filled container package | |
JP7548901B2 (en) | Container for cardioplegic solution containing bicarbonate ion and method for producing same | |
JPH10277132A (en) | Container for medical use | |
JP3832458B2 (en) | Multi-chamber container for filtration type artificial kidney replacement fluid | |
JPH114872A (en) | Medical container | |
JPH1119178A (en) | Manufacture of medical container containing medical solution with carbonic acid component | |
JP3904030B2 (en) | Multi-chamber container formulation containing replacement fluid | |
JP2750373B2 (en) | Method for stabilizing aqueous pharmaceutical solution and container | |
JP3375518B2 (en) | Injection | |
JP2002308782A (en) | Method for producing bicarbonate solution | |
JP4430500B2 (en) | Hydrogen carbonate ion-containing chemicals | |
WO2016027836A1 (en) | Platelet wash/replacement solution | |
JPH08164186A (en) | Method for sterilizing liquid agent made into single agent containing reducing sugar and bicarbonate | |
JPH11262514A (en) | Bicarbonate-containing chemical container package and carbon dioxide partial pressure control agent | |
JP6958265B2 (en) | Replenisher for blood filtration | |
HK40069437B (en) | Reservoir assembly for providing cardioplegic solution containing bicarbonate ion, and method for manufacturing the same | |
WO2004112778A1 (en) | Cisplatin preparation and process for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050712 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050926 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051009 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3733583 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081028 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111028 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141028 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |